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Abstract
The radioisotope Technetium-99m (99mTc) is used in 85%
of all nuclear medicine procedures. 99mTc is produced from
its precursor Molybdenum-99 (99Mo), whose production
is nearly all from one of only five ageing research reactors.
Recently a number of accelerator-based methods have been
proposed to fill this gap and to diversify this supply chain.
In this paper we present a compact (4 m) 10 mA, 3.5 MeV
accelerator design, to generate 99Mo via low-energy neutron
bombardment of 98Mo. We consider a Li(p,n) target for
neutron production, and propose the use of a novel moderator
to optimally shift the target output neutron spectrum into
the epithermal region of the 98Mo. This paper specifically
focuses on numerical studies for an optimised target design
capable of handling the thermal load.
INTRODUCTION
Nuclear medicine is the one of the principle hospital imag-
ing techniques in medicine (after X-ray Computed Tomogra-
phy and ahead ofMagnetic Resonance Imaging), and 85% of
the 36 million annual worldwide procedures utilise 99mTc; a
typical 99mTc procedure might be cardiac imaging to assess
risk following a heart attack. The European market is around
9 million procedures annually, where the cost of the 99mTc
in each procedure is around £10. The short 6-hour half-life
of 99mTc is diagnostically convenient, and its metastable
nature means that it only emits 143 keV gamma rays upon
decay, limiting the ancillary dose to patients (unlike other
radionuclides). Not found in nature, 99mTc is derived from
the precursor 99Mo, which is presently mostly derived com-
mercially from fission products from five ageing research
reactors [1].
The primary reactor production chain for 99Mo involves
the irradiation of highly-enriched uranium (HEU) targets,
chemical separation of the 99Mo from the fission products,
and packaging in a 99Mo/99mTc generator. The resulting
99Mo has a large specific activity typically exceeding 3000
Ci/g. However, since 2008 there has been a worsening supply
problem due to ageing and failure these reactors, particularly
the Canadian NRU reactor which presently provides half of
global production [1, 2]. In 2010 it was reported that 65%
of global production was facing shutdown. Whilst many
of the shutdowns are carefully planned to avoid overlaps,
there have been unscheduled events. There are ongoing
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efforts to adapt other reactors to produce 99Mo but there is
scientific and commercial consensus that this fragile end of
the supply chain should be diversified by also developing
accelerator-based production (see e.g. [3, 4]).
ALTERNATIVE PRODUCTION METHODS
Until around 2009 the most prominent proposed accel-
erator scheme was to use photofission of a 235U or 238U-
containing target using bremsstrahlung photons from a typi-
cally 100 mA, 50-100 MeV electron linac/tungsten target,
followed by hot-cell 99Mo extraction similar to that for re-
actor Mo [5,6]; depleted or LEU targets better meet IAEA
requirements but produce roughly twice the fission waste of
HEU, but in both cases the specific activity is similar to that
for reactor 99Mo. The large electron current offsets the low
bremsstrahlung/photofission cross-sections, but the target is
consequently difficult to cool. The principle advantage of
the photofission method is that the extraction and generator
production are largely the same as for reactor 99Mo. The
photofission route may not be cost-effective, and several
alternative methods have been proposed [3, 7–12]. Direct
cyclotron production of 99mTc in enriched 100Mo targets
using the 100Mo(p,2n)99mTc reaction has been proposed
(e.g. by TRIUMF and Uni. of Alberta) using c.17-24 MeV
protons [4, 13, 14]; licensing of the resultant 99mTc is pro-
gressing [4, 15–18]. The direct route means that the 99mTc
must be made close to its point of use, i.e. regional rather
than transnational.
An alternative route is to utilise neutron capture via
98Mo(n, γ)99Mo in either natural Mo or enriched 98Mo. Ini-
tially fast neutrons from a suitable proton conversion target
are moderated to epithermal energies to overlap the res-
onance peaks in the 98Mo capture cross-section [19, 20];
spallation targets have been proposed at high energy that
give many neutrons per proton (as advocated by Buono et
al. [21]) but these require large ( 300 m) and expensive ac-
celerator infrastructure. Low-energy targets may also be
used. AAA presently produce small quantities of commer-
cial radioisotopes (not yet 98Mo) using a c.30MeV cyclotron
with a 9Be(p,n)9B target [20, 22]. Owen has examined the
use of an existing high current (1-10 mA), 3 MeV proton
source with a 7Li(p,n)7Be target; in both Be and Li targets
the resonance overlap is limited by 1/r2 effects in the mod-
erator assembly (so a small target assembly is required), but
a graphite reflector can significantly boost the overall neu-
tron capture rate [23]. The same targets might also utilise
a subcritical uranium neutron multiplier [7, 24], but these
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targets are likely more difficult to obtain regulation for. The
difficulty in isotopically separating the 99Mo from the target
is well-known, but may not be needed if the capture rate is
large enough; more likely, one may extract 99mTc directly
from the targets similar to the cyclotron route.
PROPOSED SYSTEM
Here we consider the well-known 7Li(p,n)7Be reaction
from protons with 2.5 MeV incident energy; at this energy
several accelerator technologies may be used to deliver cur-
rents up to 10 mA (electrostatic or RFQ-based) in a compact
(c.4m) footprint. The low energy and small target allows the
use of a compact neutron moderator assembly (NMA) to
shift the fast neutron energies into the epithermal (resonant)
region for the 98Mo(n, γ)99Mo reaction. Studies show that
98Mo secondary targets placed in a suitable location within
the NMA can give diagnostically-useful specific activities
for realistic currents and irradiation times. By comparison,
a 9Be(p,n)9B target study (using MCNPX and GEANT4)
predicts that a 10 mA extracted proton current at 30 MeV
gives specific activities of 230 Ci/g/hr [23]. However, 10 mA
currents at 30 MeV will be very difficult to achieve from a
cyclotron. We propose a high current proton source, a low
energy beam transport (LEBT) and RFQ (Figure 1).
Tritium‟s radiotoxicity
10s‟ of 
  
Figure 1: schematic overview of our proposed accelerator system. Examp
Figure 1: Schematic overview of our proposed accelerator
isotope system.
Accelerators based on RFQs offer many advantages over
other technologies; RFQs can in principle transport intense
beams up to 100 mA with high beam transmission . This
gives RFQs a flexibility to operate over a very wide pa-
rameter space; RFQs have demonstrated the capability of
accelerating protons up to 8 MeV [25]. The parameters of
our proposed RFQ are: input energy 60 keV, output energy
4 MeV, current 10 mA, duty factor 6 − 100%, RF frequency
352.2 MHz, maximum Es 33MV/m, beam power 170 kW,
structure power 420 kW, total power 590 kW, total length
4.75 m.
The 7Li(p,n) reaction is well understood with extensive
experimental data and well-developed, verified, numerical
models [26, 27]; protons at 2.5MeV on 7Li(p,n) have a
c.300 mb cross-section, producing 5.5x10−8 neutrons per
incident proton. The fast neutron spectrum from a Li target
allows the use of a compact Neutron Moderator Assembly
(NMA) to shift the fast neutron energies into the epither-
mal resonant part of the 98Mo neutron capture cross-section.
The NMA we propose is based upon the design of Brett [23]
adapted from a NMA used for BNCT [28]. This design con-
sists of three main components: (1) primary target (proton
to neutron production); (2) Moderator (Neutron moderation
from the primary to secondary target; (3) Secondary target
(Neutron capture target). An overview of our NMA is shown
in figure 2. The primary target is surrounded by a layered
lead/Fluental moderator (Al+AlF3+Li) into which irradia-
tion slugs of 98Mo may be inserted at a radius optimising
the overlap neutron spectrum with the 98Mo capture cross
section. The NMA is surrounded by a Graphite reflector and
Li-loaded polyethylene shield to maximise the neutron flux
at the secondary targets.
Figure 2: Schematic overview of the primary target, neutron
moderation assembly and secondary target slug locations;
the entire assembly is a cube approximately 60 cm on a side.
Numerical simulations usingMCNP5 and Geant4 indicate
c.0.2 Ci/g/hr/mA of 99Mo activity may be obtained at the
secondary targets for a given proton current at the primary
target. With sufficient cooling it is thought that a solid Li
target may support currents up to 10 mA (i.e. 30 kW beam
power) [29], with around 3 kW demonstrated so far. Our
concept primary target design is shown schematically in
figure 3 and consists of 20cm radius 1mm thick Li target
covered with a 60µm Al layer, all on a Cu back plate 3mm
thick. The stopping power of the Al film cover was modelled
using SRIM [30], showing that a 3MeV proton beam passing
though the 60µmAl layer produce 2.5 MeV incident protons
At the Li target surface.
To determine the effects of heating and cooling in the
primary target the commercial simulation package Comsol
was used to determine effective heat transfer properties cal-
culated from the respective properties of the solid and fluid
materials that make up the primary target structure. This
model also models the effect of the interfaces between the
materials in the model to simulate the contact thermal con-
ductance coefficients, dependent on the applied stress, on
the specific conductivity in the gap, and also by accounting
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Figure 3: Schematic overview of our proposed target.
for the surface-to-surface radiation contribution between
surfaces separated by small gaps. In our model the primary
target is actively water cooled with a high water flow rate;
in Comsol the thermal effects of fluid flow are taken into ac-
count at interfaces between laminar flow and turbulent flow
by using high/low-Reynolds κ − ǫ turbulent models, where
natural buoyancy effects due to temperature differences are
accounted for by assuming a non-isothermal flow.
Simulations were conducted assuming a steady state heat
load of 30kW from the proton beam on to the Al film of the
primary target. The results of the optimised target simulation
are shown in figure 4, where it was found that the maximum
temperature in the Li target was below 170 degC, compatible
with the 180 degC melting point of the lithium target. This
was achieved with the target actively cooled by injecting
water at the base of the target system, at 0.1 Bar, 15 deg C at
0.3 m/s.
Figure 4: Expected temperature distribution of the primary
target at 30 kW beam power load.
CONCLUSION
Using the proposed 7Li(p,n) reaction allows lower-energy
proton beams to be used compared to conventional accelera-
tor approaches for technetium production, but with a higher
possible beam current, enabling this scheme to achieve a sim-
ilar specific activity to the 30MeV cyclotron 9Be(p,n)9B tar-
get discussed above. The combination of this target with our
novel moderator assembly results in potentially clinically-
useful production rates of 99mTc, although measurements
of the specific activity and extracted purity would need to be
undertaken. Although physically larger than the equivalent
cyclotron target, the proposed target assembly is not unduly
large, and could be used at laboratories with electrostatic
proton sources but no cyclotron; for example co-existing
with other uses of high-flux neutrons such as for materials
characterisation or security. Hence this scheme can help to
diversify supply of 99mTc to more locations than possible
only with reactors or cyclotrons.
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